About Candela


Candela’s brand values of Science, Results, and Trust guide its commitment to clinically proven results to strengthen the longstanding partnerships established with physicians, their practices and the patients they treat.

Established in 1970, Candela is a leading US-based global medical aesthetic device company with headquarters in Marlborough, Massachusetts. The company's technologies enable physicians to provide advanced energy-based solutions for a broad range of medical-aesthetic applications including treatment of benign vascular and pigmented lesions, scar revision, facial resurfacing, wrinkle reduction, acne, spider veins, cellulite reduction, body shaping, gynecological conditions, and tattoo and hair removal.

View Portfolio of Products

Founding Story


Candela markets, services and supports its products in nearly 100 countries, with offices in North America, Israel, France, Germany, Italy, Spain, UK, Australia, China, Japan, Hong Kong, and distributors worldwide.

Find A Distributor in your country

On the July 17th, 2017, Candela announced the successful completion of its acquisition by an affiliate of funds advised by Apax Partners. Apax Partners is a leading global private equity advisory firm.

Candela’s focus is on their customers’ success by building on the strength of Candela’s brands, the technology behind its products, and the high quality of the company’s engineering and product development organization.

Charity Support


Candela supports various charities by using our technologies to help patients with traumatic scarring, vascular defects, birth marks and other painful or socially debilitating problems.

Company Timeline

2022

GentleMax Pro Plus® launched

Higher fluences, larger spot sizes and shorter pulse durations.

2021

Frax Pro® system introduced

With Frax 1550™ and Frax 1940™ handpieces.


FDA clearance of Frax 1940 for pigmentation.

2020

Exceed microneedling device introduced

Latest technology that’s quickly replacing dermal rollers and other anti-aging methods on the market.


Two PicoWay handpieces launched

730 nm and Resolve Fusion™ 532 nm

2019

Candela Corporation

Syneron-Candela rebrands as Candela.
New global HQ in Marlborough, MA.


Nordlys platform introduced

High ROI fractional non-ablative resurfacing capabilities.


PicoWay Resolve Fusion and 4th wavelength introduced

2018

Vbeam® Prima

The Vbeam Prima system with an advanced 595nm pulsed dye laser (PDL) and 1064nm wavelength, receives FDA clearance.


Ellipse IPL

Syneron-Candela acquires Ellipse A/S adding renowned Ellipse IPL to portfolio.

2017

Acquisition

APAX Partners acquires Syneron Candela.

2016

PicoWay® Resolve Handpiece

Syneron Candela introduces the PicoWay Resolve handpiece with a 3rd wavelength.


CO2RE® Intima Handpiece

The CO2RE Intima system for feminine health is launched.

2015

Profound®

Profound system - the first long-pulse, temperature-controlled RF microneedling device, is launched.


PicoWay®

PicoWay, a 2-wavelength laser platform is introduce.

2012

GentleMax Pro® launched

A dual wavelength laser platform that combines the fastest and most powerful 755 nm Alexandrite laser with an equally powerful 1064 nm Nd:YAG laser.


UltraShape®

UltraShape, the first pulsed ultrasound system for fat reduction is acquired.

2011

GentleLase Pro®

The GentleLase Pro system is launched.

2010

Acquisition

Syneron acquires Candela.

2009

CO2RE®

The CO2RE aesthetic platform is launched. CO2RE system is a CO2 based device for facial treatments.

2008

AlexTriVantage®

The AlexTriVantage system for advancing tattoo and pigmented lesion treatment, is launched.


elos Plus® - eTwo®

Syneron launches the elōs Plus, eTwo and eMatrix systems.

2007

VelaShape® II

The VelaShape II system is launched.

2005

Vbeam Perfecta®

Vbeam Perfecta system, a gold standard for vascular treatments is launched.

2004

Syneron files an IPO

VelaShape®

Syneron launches the VelaShape device for improvement in cellulite.

2002

Smoothbeam 1450 nm

Smoothbeam 1450 nm diode laser is launched for acne vulgaris and more.

2000

elōs® technology

Syneron develops the elōs technology.

1998

Candela receives FDA clearance for the Alexandrite laser for permanent hair reduction.

1993

Candela launches first Q-switched laser for pigment and tattoos.

1986

FDA clearance received for SPTL1, the gold standard for vascular laser treatments.

1883

Candela, with MGH, develops SPTL1, the first pulsed dye laser.

1970

Candela founded as an industrial laser company.

Join Our Team


At Candela, you get to enable medical practices to build their businesses, help patients around the world improve their confidence and work with all kinds of talented individuals globally. We focus on execution and teamwork, enabling employees to build their careers, have fun accomplishing great things.
Geoffrey Crouse, CEO

View available positions


Back to top

We use cookies on this site to enhance your user experience.

By continuing to browse you are agreeing to our use of cookies